John F. Crowley - Dec 15, 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: Executive Chairman, Director
Signature: /s/ Christian Formica, Attorney-in-Fact
Stock symbol: FOLD
Transactions as of: Dec 15, 2023
Transactions value $: -$76,516
Form type: 4
Date filed: 12/19/2023, 05:55 PM
Previous filing: Dec 5, 2023
Next filing: Jan 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FOLD	Common Stock	Sale	-$76.5K	-6.04K	-0.68%	$12.66	878K	Dec 15, 2023	Direct	F1
transaction	FOLD	Common Stock	Award	$0	+34.6K	+3.94%	$0.00	912K	Dec 18, 2023	Direct	F2
holding	FOLD	Common Stock						64.9K	Dec 15, 2023	By Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company.

Content

This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022. In addition to the reported transactions, Mr. Crowley also has approximately 845,000 options outstanding and exercisable at various strike prices.